Plain-English translation of NCT06119997 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a screening strategy to catch advanced liver scarring (fibrosis) early, before you have any symptoms. The study uses a simple blood test called FIB-4 as the first step. If your FIB-4 score suggests possible advanced scarring, you'll have a more specialized blood test to confirm the diagnosis.
Many people have liver damage from conditions like hepatitis or fatty liver disease but don't know it because there are no symptoms. By identifying advanced scarring early through blood tests, doctors may be able to start treatment sooner and prevent serious complications.
You likely qualify if…
You likely don't qualify if…
You'll have blood drawn for the FIB-4 test at a local laboratory, which measures liver enzymes and platelet counts. If your score is elevated, you'll return for a second specialized blood test to confirm whether you have advanced liver scarring. The study involves these blood tests and follow-up with the liver specialists at the hospital if needed.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
France
Enrollment target
~500 participants
Started
June 2025
Primary completion
April 2028
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Charlotte Costentin, Pr
University Hospital, Grenoble
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.